Boule Diagnostics publishes Annual Report for 2011, and audit report with remark
In light of the shortcomings that existed during 2011 in the parent company regarding fees and charges, Boule notes that the delays are not due to lack of liquidity but due to temporary shortcomings in the administrative procedures. The latter has been corrected so that the problem will not be repeated. The delays in payment have only incurred negligible costs for the company.
For more information, please contact:
Ernst Westman, President CEO of Boule Diagnostics AB
Phone: 0708-60 88 63, e-mail: ernst.westman@boule.se
TILL REDAKTÖRERNA
Om Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic. www.boule.se
Latest news
-
Boule Diagnostics delårsrapport Q2 2025 18 Jul, 2025
-
Boule Diagnostics Interim Report Q2 2025 18 Jul, 2025
-
Boule Diagnostics – Inbjudan till presentation av Q2 2025 11 Jul, 2025
-
Boule Diagnostics – Invitation to presentation of the interim report Q2 2025 11 Jul, 2025
-
Bulletin from the Annual General Meeting May 7, 2025 in Boule Diagnostics 7 May, 2025
-
Kommuniké från Boule Diagnostics årsstämma den 7 maj 2025 7 May, 2025
-
Boule Diagnostics delårsrapport Q1 2025 28 Apr, 2025
-
Boule Diagnostics Interim Report Q1 2025 28 Apr, 2025